Advertisement

European Journal of Dermatology

, Volume 28, Issue 5, pp 661–667 | Cite as

Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome

  • Barbara BregeonEmail author
  • Jean-Michel Nguyen
  • Emilie Varey
  • Gaelle Quereux
  • Mélanie Saint-Jean
  • Lucie Peuvrel
  • Amir Khammari
  • Brigitte Dreno
Clinical report
  • 2 Downloads

Abstract

Background

For melanoma patients, surgery is a standard treatment for locoregional skin metastasis (LSM).

Objectives

To assess the frequency, and risk factors for positive margins after excision of LSM and their impact on patient overall survival (OS) and progression-free survival (PFS).

Materials & methods

A monocentric, retrospective observational study was performed including 87 patients with LSM who had undergone surgical excision.

Results

Positive margins were found in 45% of patients after excision. After additional excision, 28% of patients still had positive margins. Interestingly, there was no difference in PFS or OS for clear margins after the first or additional excision or for margins that remained positive without additional excision. LSM size was the only identified predictive factor for positive margins.

Conclusion

This is the first reported study investigating the frequency of, and risk factors for positive margins of cutaneous LSM, which raises the question of whether additional excision should be performed following positive margin excision.

Key words

melanoma locoregional skin metastasis surgery positive margin overall survival progression-free survival risk factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.CrossRefGoogle Scholar
  2. 2.
    Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the USA, Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014; 170: 20–30.CrossRefGoogle Scholar
  3. 3.
    Balch CM, Gershenwald JE, Soong S–J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–206.CrossRefGoogle Scholar
  4. 4.
    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence–based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472–92.CrossRefGoogle Scholar
  5. 5.
    Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in–transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983; 198: 65–9.CrossRefGoogle Scholar
  6. 6.
    Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15: 1039–51.CrossRefGoogle Scholar
  7. 7.
    Balch CM. Microscopic satellites around a primary melanoma: another piece of the puzzle in melanoma staging. Ann Surg Oncol 2009; 16: 1092–4.CrossRefGoogle Scholar
  8. 8.
    Shaikh L, Sagebiel RW, Ferreira CMM, Nosrati M, Miller JR, Kashani–Sabet M. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol 2005; 141: 739–42.CrossRefGoogle Scholar
  9. 9.
    Weide B, Faller C, Büttner P, et al. Prognostic factors of melanoma patients with satellite or in–transit metastasis at the time of stage III diagnosis. PLoS One 2013; 8: e63137.CrossRefGoogle Scholar
  10. 10.
    Messeguer F, Agustí–Mejías A, Traves V, et al. Mitotic rate and subcutaneous involvement are prognostic factors for survival after recurrence in patients with only locoregional skin metastasis as the first site of recurrence from cutaneous melanoma: survival after locoregional skin metastasis. J Eur Acad Dermatol Venereol 2013; 27: 436–41.CrossRefGoogle Scholar
  11. 11.
    Suojärvi NJ, Jahkola TA, Virolainen S, Ilmonen SK, Hernberg MM. Outcome following local recurrence or in–transit metastases in cutaneous melanoma. Melanoma Res 2012; 22: 447–53.CrossRefGoogle Scholar
  12. 12.
    Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016; 14: 450–73.CrossRefGoogle Scholar
  13. 13.
    Turley RS, Raymond AK, Tyler DS. Regional treatment strategies for in–transit melanoma metastasis. Surg Oncol Clin N Am 2011; 20: 79–103.CrossRefGoogle Scholar
  14. 14.
    Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven–year experience. Ann Surg 1974; 180: 635–43.CrossRefGoogle Scholar
  15. 15.
    Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T–VEC) for the treatment of advanced melanoma. Immunotherapy 2015; 7: 611–9.CrossRefGoogle Scholar
  16. 16.
    Liu H, Innamarato PP, Kodumudi K, et al. Intralesional Rose Bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1. Oncotarget 2016; 7: 37893–905.Google Scholar
  17. 17.
    Grotz TE, Mansfield AS, Erickson LA, Otley CC, Markovic SN, Jakub JW. In–transit melanoma: an individualized approach. Oncology 2011; 25: 1340.Google Scholar
  18. 18.
    Leventhal JS, Odell ID, Imaeda S, Maverakis E, King BA. Treatment of melanoma in–transit metastases with combination intralesional interleukin–2, topical imiquimod, and tretinoin 0.1% cream. JAAD Case Rep 2016; 2: 114–6.CrossRefGoogle Scholar
  19. 19.
    Madu MF, Deken MM, van der Hage JA, Jóźwiak K, Wouters MWJM, van Akkooi ACJ. Isolated limb perfusion for melanoma is safe and effective in elderly patients. Ann Surg Oncol 2017; 24: 1997–2005.CrossRefGoogle Scholar
  20. 20.
    Rauch A, Cazzato RL, Garnon J, et al. MRI–guided cryoablation of in–transit metastases from cutaneous melanoma: a brief report on a preliminary experience. Cardiovasc Intervent Radiol 2017; 40: 1285–9.CrossRefGoogle Scholar
  21. 21.
    Mangold AR, Skinner R, Dueck AC, Sekulic A, Pockaj BA. Risk factors predicting positive margins at primary wide local excision of cutaneous melanoma. Dermatol Surg 2016; 42: 646–52.CrossRefGoogle Scholar
  22. 22.
    Read RL, Haydu L, Saw RPM, et al. In–transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol 2015; 22: 475–81.CrossRefGoogle Scholar
  23. 23.
    Zhang J, Miller CJ, Sobanko JF, Shin TM, Etzkorn JR. Frequency of and factors associated with positive or equivocal margins in conventional excision of atypical intraepidermal melanocytic proliferations (AIMP): a single academic institution cross–sectional study. J Am Acad Dermatol 2016; 75: 688–95.CrossRefGoogle Scholar
  24. 24.
    Miller CJ, Shin TM, Sobanko JF, et al. Risk factors for positive or equivocal margins after wide local excision of 1345 cutaneous melanomas. J Am Acad Dermatol 2017; 77: 333–40.e1.CrossRefGoogle Scholar

Copyright information

© John Libbey Eurotext 2018

Authors and Affiliations

  • Barbara Bregeon
    • 1
    Email author
  • Jean-Michel Nguyen
    • 1
    • 2
  • Emilie Varey
    • 1
    • 3
  • Gaelle Quereux
    • 1
    • 3
  • Mélanie Saint-Jean
    • 1
    • 3
  • Lucie Peuvrel
    • 1
    • 3
  • Amir Khammari
    • 1
    • 3
  • Brigitte Dreno
    • 1
    • 3
  1. 1.Service de dermatologie, Hôtel-DieuCHU de NantesNantesFrance
  2. 2.PIMESP-SEBSaint-Jacques HospitalNantesFrance
  3. 3.Service de dermatologie, CIC 1413, CRCINA INSERM 1232CHU de NantesNantesFrance

Personalised recommendations